These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28541024)

  • 1. The clinical significance of neoadjuvant chemotherapy in improving the drug resistance of osteosarcoma.
    Wan Y; Xu L; Zhuo N; Ge J; Chen G; Lu XB
    Minerva Med; 2017 Oct; 108(5):479-481. PubMed ID: 28541024
    [No Abstract]   [Full Text] [Related]  

  • 2. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
    Yu W; Tang L; Lin F; Yao Y; Shen Z
    Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for osteosarcoma without high-dose methotrexate: another piece in the puzzle.
    Blay JY
    Onkologie; 2007 May; 30(5):226-7. PubMed ID: 17460415
    [No Abstract]   [Full Text] [Related]  

  • 4. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
    Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
    Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant/primary chemotherapy in cancer treatment: what advantage?
    Wynendaele W; van Oosterom AT
    Forum (Genova); 1999; 9(3):212-21. PubMed ID: 10504169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy.
    Bacci G; Briccoli A; Longhi A; Ferrari S; Mercuri M; Faggioli F; Versari M; Picci P
    Acta Oncol; 2005; 44(7):748-55. PubMed ID: 16227167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: a comparison of results obtained in single-institution and multicenter trials.
    Bacci G; Mercuri M; Longhi A; Setola E; Gozzi E; Forni C
    Chir Organi Mov; 2004; 89(4):283-92. PubMed ID: 16048049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy resistance in osteosarcoma: current challenges and future directions.
    Chou AJ; Gorlick R
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1075-85. PubMed ID: 16831079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of ifosfamide in neoadjuvant therapy for osteosarcoma].
    Orthopade; 2013 Dec; 42(12):1072. PubMed ID: 24482827
    [No Abstract]   [Full Text] [Related]  

  • 11. [Role of chemotherapy in treatment of osteosarcoma].
    Perek D; Jurczyk-Procyk S
    Pediatr Pol; 1995 Nov; 70(11):939-47. PubMed ID: 8677160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Bone-targeted Drug Delivery Systems for Neoadjuvant Chemotherapy for Osteosarcoma.
    Li CJ; Liu XZ; Zhang L; Chen LB; Shi X; Wu SJ; Zhao JN
    Orthop Surg; 2016 May; 8(2):105-10. PubMed ID: 27384718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
    Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
    J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
    Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
    J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
    BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma.
    Ferrari S; Palmerini E
    Curr Opin Oncol; 2007 Jul; 19(4):341-6. PubMed ID: 17545797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant treatment in osteosarcomas].
    Kalifa C; Brugières L; Le Deley MC
    Bull Cancer; 2006 Nov; 93(11):1115-20. PubMed ID: 17145581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatment of high grade osteosarcoma of the extremity: review.
    Bacci G; Lari S
    J Chemother; 2001 Jun; 13(3):235-43. PubMed ID: 11450880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience.
    Bacci G; Balladelli A; Palmerini E; Alberghini M; Pollastri P; Galletti S; Mercuri M; Picci P
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):908-12. PubMed ID: 19131777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy with high-dose methotrexate in osteosarcoma.
    Mir O; Ropert S; Goldwasser F
    Lancet Oncol; 2008 Dec; 9(12):1198. PubMed ID: 19038767
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.